- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01762696
A Real-time, Contextual Intervention Using Mobile Technology to Reduce Marijuana Use in Youth (MOMENT)
A Real-time, Contextual Intervention Using PDAs to Reduce Marijuana Use in Youth
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study proposes a pilot randomized trial to further develop and test the Momentary Self-Monitoring and Feedback + Motivational Enhancement Therapy (MOMENT) intervention, a real-time, contextual intervention to reduce marijuana use over three months in 15-to-24-year-old primary care patients who use frequently. We will randomize youth to one of two arms (goal 30 per arm completing 3-month follow-up): 1) MOMENT (MET + momentary self-monitoring + context-dependent feedback), or 2) MET-only. The two study arms will permit evaluation of the contributions of the self-monitoring and feedback components of the intervention above-and-beyond the MET and directly test the influence of the intervention on the link between momentary context and marijuana-related outcomes.
The specific aims of the study are
Specific Aim 1: Continued Feasibility Evaluation. In our preliminary work, we demonstrated that 1) youth perceive MOMENT to be easy to understand, comfortable, motivating, and helpful in reducing their marijuana use, 2) we can recruit 4 participants/month (minimum rate for the proposed study), and 3) we can successfully implement a MOMENT intervention study in the proposed recruitment sites. Based on this work, we have identified additional areas of feasibility on which to focus in the proposed study. Specifically, we aim to achieve:
1a. A signal response rate of at least 70% during each of three periods of momentary data collection - baseline, intervention, and 3-month follow-up.
1b. A diary response rate of at least 70% during each momentary data collection period
c. A retention rate of at least 80% of participants at the 3-month follow-up.
Specific Aim 2. Early-Stage Efficacy Exploration. Our preliminary work showed that both momentary and individual-level outcomes improved from baseline to three months post-intervention. The primary momentary outcomes are desire to use marijuana when in a triggering context and likelihood of use following exposure to a triggering context. The primary individual-level outcomes are number of use events/week, 30-day percent of days abstinent, dose/use event, and measures of motivation (importance of, readiness for, and confidence about reducing use). Based on the preliminary findings, we will explore these early-stage efficacy questions:
- a. Will improvements in momentary outcomes be observed with MOMENT, but not MET-only?
(1) The association between exposure to self-identified trigger contexts and momentary desire to use marijuana will be attenuated at three months, compared to pre-intervention.
(2) The likelihood of marijuana use following exposure to a trigger context will be reduced at three months.
2b. Will improvements in individual-level outcomes be greater with MOMENT vs. MET-only?
- The reduction in marijuana use frequency (events/week and 30-day percent of days abstinent) and dose (per use event) will be greater at three months.
- The increase in motivation to reduce or discontinue use will be greater at three months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Boston Children's Hospital Adolescent/Young Adult Medical Clinic
-
Jamaica Plain, Massachusetts, United States, 02130
- Martha Eliot Health Center Adolescent Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female between the ages of 15-24 years
- Patient of the Boston Children's Hospital Adolescent/Young Adult Medicine Clinic or Martha Elliot Health Center Adolescent Clinic
- Ability to read and understand English
Exclusion Criteria:
- Medically or emotionally unstable, intoxicated or "high,", or otherwise unable to give consent at the time of their appointment
- Have previously participated in this study
- Does not meet the above inclusion criteria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: MET only
Motivational Enhancement Therapy only
|
Motivational Enhancement Therapy only
Other Names:
|
Experimental: MOMENT
The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
|
Motivational Enhancement Therapy only
Other Names:
The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Marijuana desire
Time Frame: 3 months
|
Desire to use marijuana when in top-3 trigger context
|
3 months
|
Marijuana use following trigger exposure
Time Frame: 3 months
|
Marijuana use following exposure to top-3 trigger context
|
3 months
|
Frequency of marijuana use
Time Frame: 3 months
|
Marijuana use events/day
|
3 months
|
Percent days abstinent
Time Frame: 3 months
|
30-day percent days abstinent from marijuana use
|
3 months
|
Motivation to reduce marijuana use
Time Frame: 3 months
|
Daily score on 3 scales - readiness to reduce marijuana use, importance of reducing use, and confidence in ability to reduce use
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lydia A Shrier, MD, MPH, Boston Children's Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1R34DA030535-01A1 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Marijuana Abuse
-
Dartmouth-Hitchcock Medical CenterCompletedMarijuana Abuse and DependenceUnited States
-
Brown UniversityCompleted
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA); Research Foundation for Mental Hygiene...CompletedMarijuana SmokingUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)Completed
-
State University of New York at BuffaloCompleted
-
York UniversityUniversity of ManitobaCompletedMarijuana Use | Marijuana DependenceCanada
-
National Institute on Drug Abuse (NIDA)Completed
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA); Research Foundation for Mental Hygiene...Completed
-
Yale UniversityNational Institute on Drug Abuse (NIDA); Hartford Hospital; Maastricht University and other collaboratorsCompletedMarijuana ImpairmentUnited States
Clinical Trials on MET
-
Elcelyx Therapeutics, Inc.CompletedHealthy Subjects
-
NuBiyotaUnknownObesity, Metabolically BenignCanada
-
Dow University of Health SciencesCompletedMechanical Neck PainPakistan
-
University of ConnecticutNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol ConsumptionUnited States
-
National Jewish HealthNational Heart, Lung, and Blood Institute (NHLBI); The Miriam Hospital; National...CompletedSleep Apnea, Obstructive | Continuous Positive Airway PressureUnited States
-
Elcelyx Therapeutics, Inc.CompletedType 2 Diabetes MellitusUnited States, Puerto Rico
-
Foundation University IslamabadRecruiting
-
Triemli HospitalCompleted
-
York UniversityUniversity of ManitobaCompletedMarijuana Use | Marijuana DependenceCanada
-
Universidade Norte do ParanáWithdrawn